• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

25.09.2017

Teva Announces Reintroduction of Generic Depo-Provera® in the United States

JERUSALEM--(BUSINESS WIRE)--Sep. 25, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL, in the United States. Medroxyprogesterone acetate injectable suspension is a progestin indicated only for the prevention of pregnancy. “This reintroduction brings an additional product to a market that was previously lacking in options,” said Dr. Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D. “In addition to its importa...
19.09.2017

Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO® (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States

JERUSALEM & SAN FRANCISCO--(BUSINESS WIRE)--Sep. 19, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Nuvelution Pharma, Inc. today announced their partnership to develop AUSTEDO® (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome (TS) in pediatric patients in the United States. This partnership will accelerate development of Austedo® in TS, hopefully bringing a much needed new treatment option to affected young patients more quickly. This novel agreement provides a creative risk-sharing funding framework for progressing a promising pipeline opportunity into an approv...
19.09.2017

Teva Completes Amendment to Credit Facilities

Amendment Recasts Leverage Ratio Covenant Requirements JERUSALEM--(BUSINESS WIRE)--Sep. 19, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced amendments to its USD and JPY term loan and revolving credit facilities, providing Teva greater flexibility in its financial leverage ratio covenants. The amended leverage ratio covenants in the credit agreements permit a maximum leverage ratio of 5.0 times through and including December 31, 2018, gradually declining to 3.5 times by December 31, 2020. As of June 30, 2017, the aggregate principal amount collectively outstanding under the USD...
18.09.2017

New Initiative Creates Scalable Solutions to Improve Care of Patients with Multiple Chronic Conditions

Teva and Mount Sinai Health System pursue new models to reduce cost and complexity of care JERUSALEM & NEW YORK--(BUSINESS WIRE)--Sep. 18, 2017-- Today, two leading private sector groups announced a partnership to create scalable solutions to improve patient and health system care for Multiple Chronic Conditions. The initiative was announced to an audience of public health leaders at the World Economic Forum’s (WEF) Sustainable Development Impact Summit. The meeting, which formed a part of the Summit, was convened to advocate for action to address Multiple Chronic Conditions (MCC), an emerging and unaddressed g...
18.09.2017

Teva Announces Sale of Remaining Assets in Specialty Global Women’s Health Portfolio for $1.38 Billion

Company executes sale agreements for planned divestiture of global women’s health business to generate total proceeds of $2.48 billion Women’s health sales, alone, close to $2 billion net target of total non-core asset divestiture JERUSALEM--(BUSINESS WIRE)--Sep. 18, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has entered into two agreements to sell the remaining assets of its specialty global women’s health business for $1.38 billion. Proceeds from these sales, combined with proceeds from the recently announced sale of PARAGARD® total $2.48 billion and wi...
14.09.2017

Teva to Present Data for AUSTEDO® (deutetrabenazine) Tablets and Other Research at the 2017 Psych Congress

JERUSALEM--(BUSINESS WIRE)--Sep. 14, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the presentation of 12 posters at the upcoming 2017 Psych Congress, September 16-19 in New Orleans, Louisiana. The clinical and health economics data to be presented include additional analyses from two pivotal Phase III trials, AIM-TD and ARM-TD, as well as safety data evaluating AUSTEDO® (deutetrabenazine) tablets in tardive dyskinesia (TD). “Teva’s data at the 2017 Psych Congress shed light on the importance of recognizing the day-to-day impact of living with tardive dyskinesia,” said Michael Hay...
12.09.2017

Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

JERUSALEM--(BUSINESS WIRE)--Sep. 12, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental New Drug Application (sNDA) for the use of TRISENOX® (arsenic trioxide) injection in combination with all-trans retinoic acid (ATRA) for induction of remission and consolidation in patients with newly diagnosed low or intermediate risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. Currently, TRISENOX® is indicated for induction...
11.09.2017

Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical

Company takes first step in planned divestment of non-core assets JERUSALEM--(BUSINESS WIRE)--Sep. 11, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has entered into a definitive agreement under which CooperSurgical will acquire PARAGARD® (intrauterine copper contraceptive), a product within its global Women’s Health business, in a $1.1 billion cash transaction. PARAGARD® had revenues of approximately $168 million for the trailing twelve month period ending June 30, 2017. This transaction includes Teva’s manufacturing facility in Buffalo, NY, which produces PARAGARD® exclusively. ...
11.09.2017

Teva Names Kåre Schultz as President and Chief Executive Officer

Brings 30 Years of Global Pharmaceutical and Healthcare Experience, Including Leadership Positions at Lundbeck and Novo Nordisk Proven Track Record of Implementing Turnaround Strategies JERUSALEM--(BUSINESS WIRE)--Sep. 11, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that its Board of Directors has named Kåre Schultz to become the Company’s President and Chief Executive Officer. Mr. Schultz will succeed Dr. Yitzhak Peterburg, who will continue to serve as Interim Chief Executive Officer until Mr. Schultz joins the Company. Today’s leadership announcement represents the successful co...
09.09.2017

Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine

Late-Breaking Data Presented at IHC Highlight Primary and Secondary Outcome Measure Results from Chronic and Episodic Migraine Phase III Clinical Trials JERUSALEM--(BUSINESS WIRE)--Sep. 9, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) has presented new data evaluating fremanezumab, an investigational treatment for the prevention of migraine, at the 18th Congress of the International Headache Society (IHC) in Vancouver, Canada. Data presented across two platform presentations and five late-breaking abstracts featured detailed, positive efficacy results from pivotal Phase III HALO studies of fremanezu...